Skip to main content
. 2023 Mar 5;15(1):2180794. doi: 10.1080/19420862.2023.2180794

Figure 1.

Figure 1.

Tetravalent design of anti-PD1/CTLA-4 bispesific antibody cadonilimab based on co-expression of PD-1 and CTLA-4 in tumor tissue. (a) Correlation analysis of PD-1 and CTLA-4 mRNA expression levels in various tumor types from TCGA dataset using cBioportal. The X- and Y-axis represent the mRNA expression level transformed by Log(value+1). TCGA, The Cancer Genome Atlas. (b) Schematic diagram of cadonilimab tetravalent structure.